Navigation Links
Tris Pharma Announces Appointment of Dr. Mahdi Fawzi as Top R&D Executive
Date:1/25/2012

MONMOUTH JUNCTION, N.J., Jan. 25, 2012 /PRNewswire/ -- Tris Pharma, an emerging specialty pharmaceutical company announced joining of a highly regarded Big Pharma executive Dr. Mahdi Fawzi to its leadership position as the Chief Scientific Officer and Executive Vice President of R&D including Regulatory Affairs.  

Throughout his career Dr. Fawzi has helped create a huge value as exemplified having many blockbuster drugs developed under his leadership such as Lipitor®, Enbrel®, Protonix®, Effexor XR®, Rapamune®, and Pristiq® among other.  Most recently Dr. Fawzi was President, Global Research & Development at Warner Chilcott where he led approval of Atelvia™ and Loestrin 24Fe, and managed integration of P&G's Pharmaceutical R&D operation. From 1995 to 2009, Dr. Fawzi was part of senior leadership team at Wyeth including last five years as Executive Vice President of Preclinical Development. Under his leadership Wyeth advanced 91 new molecules, filed 70 INDs, and 10 NDAs over last seven years prior to Pfizer merger. He oversaw 1300 scientists worldwide and managed a budget of over a quarter billion dollars. While at Wyeth, he won several prestigious industry awards and was one of the four finalists in 2004 for the Pharmaceutical Executive of the Year Award. He also held senior management positions at Warner Lambert and P&G. He is an author or co-author of over 50 publications and awarded more than 80 patents. He is a pharmacist by education and earned his M.S. and Ph.D. in Pharmaceutical Chemistry at University of Michigan.

"We are fortunate to have someone of Dr. Fawzi's caliber lead Tris R&D. Mahdi will lead our development, strengthen research base of various technology initiatives that are underway, direct clinical and regulatory disciplines," said Ketan Mehta, Tris' President and CEO. "Dr. Yu-Hsing Tu, who has led R&D for last ten years will focus on product development and report to Mahdi." 

"I am truly excited to be part of Tris' pioneering work involving new technologies, especially OralXR+ platform and its application in liquid and other unique dosage forms," stated Dr. Mahdi Fawzi. "Tris has accomplished a great deal in its relatively short history and I look forward to building upon the successes Dr. Tu and the R&D team has had to date."

About Tris Pharma

Tris Pharma is an emerging specialty pharmaceutical company focused on the research and development of drug delivery technologies based products. Through its OralXR+ platform, Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' Nobuse™ platform provides abuse-deterrence for opioids and other abuse-prone drugs. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey, USA. For more information, please visit www.trispharma.com.


'/>"/>
SOURCE Tris Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/8/2017)... Fla. , June 8, 2017  Less than ... that hit more than 200,000 companies, including hospital networks, ... being heralded as one of the largest online extortion ... in the healthcare market, it is imperative that providers ... protect their data from this — and many other ...
(Date:6/7/2017)... June 7, 2017 Endo International plc (NASDAQ: ... 2017, the Hon. Joseph R. Goodwin , U.S. ... West Virginia , entered a case management ... Repair System Products Liability Litigation (the "MDL") that includes ... to provide expert disclosures on specific causation within one ...
(Date:6/5/2017)... 2017 The Cincinnati location ... Inc. (NYSE: DPLO), has been awarded a Top Workplaces ... Results are based on an employee survey administered by ... workplace improvement. The survey measures several aspects of workplace culture, ... ...
Breaking Medicine Technology:
(Date:6/26/2017)... ... 26, 2017 , ... New patients with missing teeth in Fitchburg, ... a referral. Dr. Cotey is a trusted dentist who has placed many dental implants ... Patients with missing teeth in Fitchburg, WI, are encouraged to find out if they ...
(Date:6/25/2017)... ... June 24, 2017 , ... Create a feel-good lyric music video in Final Cut Pro X ... the timeline and write in the lyrics to any song. ProLyric flies in the text ... of the text can be added modularly for optimal control. ProLyric makes editing any music ...
(Date:6/25/2017)... ... 25, 2017 , ... An increase in wetter weather in the Northern California ... with that; a humdinger of an allergy season. A relief from drought conditions is ... misery-causing grass and weed pollen. , “Our patients have been reporting the typical ...
(Date:6/25/2017)... ... ... With a heatwave currently bearing down on Northern California pushing temperatures to the maximum, many ... is easy with laser hair removal. , The process of summer waxing and constantly ... all you want to do is get out, dive in and cool off. There is ...
(Date:6/24/2017)... , ... June 24, 2017 , ... ... offering genetic testing for medications in select Florida and Texas doctors' offices and ... , This new application of genetic testing recognizes the role genes play in ...
Breaking Medicine News(10 mins):